Investir pour l’avenir en dénichant les sociétés nord-américaines les plus novatrices.
Fund Type |
Portfolio composition (typical hypothetical weighting) |
| North American equity with U.S. equity bias | 20-30 U.S. and Canadian stocks |
Benchmark |
Target return: |
| S&P 500 Index (in CDN $) and S&P/TSX Composite Index (pro-rated to portfolio mix) | Outperform benchmark over longterm periods |
Volatility control: |
|
| Diversification across market caps, growth stages of companies and across U.S. and Canadian sectors | |
Code de fonds |
Début |
||
| Frais d’acquisition: | MAV108 | Class A: | 04.06.98 |
| DSC: | MAV208 | Class F: | February 7, 2006 |
| Low-load DSC: | MAV508 | ||
| F Class: | MAV728 | ||
Distribution |
RRSP Eligibility |
||
| Annually | 100% | ||
Capitaux totaux (000’s) |
NAVPS |
||
| $5,656 | $1.92 | ||
| 1 | Apple Computer Inc. | 6.7% |
| 2 | Gilead Sciences Inc. | 6.5% |
| 3 | Orbital Sciences Corporation | 6.5% |
| 4 | Gen-Probe Inc. | 6.0% |
| 5 | Celgene Corporation | 5.9% |
| 6 | Moog Inc. | 5.7% |
| 7 | Monsanto Company | 5.6% |
| 8 | Activision Inc. | 5.5% |
| 9 | Deere and Company | 5.5% |
| 10 | Electronic Arts Inc. | 5.2% |
| mois1 | -3.52% |
| mois3 | -14.29% |
| mois6 | -18.64% |
| YTD | -27.00% |
| année1 | -26.72% |
| année2 | -12.19% |
| année3 | -1.52% |
| année5 | -0.21% |
| année10 | 0.00% |
| année15 | 0.00% |
| année20 | 0.00% |
| depuis la début | -1.23% |
| Industrial | 30.8% |
| Biotech/Health Care | 24.8% |
| Information Technology | 21.6% |
| Consumer Discretionary | 15.3% |
| Agriculture & Chemical | 5.6% |
| Other | 1.8% |
| US Equities | 98.2% |
| Cash & Equivalent | 1.8% |
Steve Rogers
Vice-présidente et gestionnaire de portefeuilles
Gestion de fonds Mavrix inc.
Innovation in an economic sense refers to the successful exploitation of new ideas. These could be new and useful products, services, new methods of production or new business models. Pursued effectively, innovation can improve competitive positioning, market share, time-to-market, quality, efficiency and productivity. Companies that successfully innovate can establish and maintain significant advantages over those that don’t.
When we believe in the opportunity provided by an investment in a specific company, we want it to be capable of contributing meaningfully to the performance of the portfolio. While we still maintain a prudent level of diversification, we do not want to diversify away the returns that we have set out to capture as our primary objective.
The Mavrix Enterprise Fund is 100% RRSP eligible. For non-RRSP/RRIF investing, the Fund has significant capital loss carryforwards which will offset future capital gains to reduce or negate any taxable distributions.
“The Mavrix Enterprise Fund aims to participate in the growth of North America’s most innovative companies in a concentrated portfolio.”